in land-applied sewage sludge (biosolids);Envirol Sci Technol;2001; 35(24):4798-804 Lee MH; Kim E; Kim TS. Exposure to 4-tert-octylphenol, an environmentally persistent alkylphenol, enhances interleukin-4 production in T cells via NF-AT activation. Toxicol Appl Pharmacol;2004; 197(1):19-28 Li Z, Ma JY, Kerr I, Chakravarty S, Dugar S, Schreiner G, Protter AA: Selective inhibition of p38 MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury. Am J Physiol Heart Circ Physiol, 291: H1972-H1977; 2006. Lin TH, Metzger A, Diller DJ, Desai M, Henderson I, Ahmed G, Kimble EF, Quadros E, Webb ML: Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors. J Pharmacol Exp Ther, 318:495-502; 2006. Lores M; Llompart M; Sanchez-Prado L; Garcia-Jares C; Cela R. Confirmation of the formation of dichlorodibenzo-p-dioxin in the photodegradation of triclosan by photo-SPME. Anal Bioanal Chem;2005; 381(6):1294-8 Lu Q, Qiu T-Q, Yang H: Ligustilide inhibits vascular smooth muscle cells proliferation. Eur J Pharmacol, 542:136-140; 2006. Malemud CJ: Small molecular weight inhibitors of stress activated and mitogen-activated protein kinases. Mini Rev Med Chem, 6:689-698; 2006. Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, OYong G, Kapoun AM et al: A selective p38 mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther, 318:132-141; 2006. Meyer LH, Pap T: MAPK signalling in rheumatoid arthritis destruction: can we unravel the puzzie? Arthritis Res Ther, 7: 177-178; 2005. Miwatashi S, Arikawa Y, Kotani e, Miyamoto M, Naruo K, Kimura H, Tanaka T, Asahi S, Ohkawa S: Novel inhibitor of p38 MAP kinase an an anti-TNF- drug: discovery of N-(4-(2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl)-2-pyridyl) benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem; 48: 5966-5979; 2005. Ohren Jf, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C et al.: Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol, 11: 1192-1197; 2004. Okubo T; Yokoyama Y; Kano K; Kano I. ER-dependent estrogenic activity of parabens assessed by proliferation of human breast cancer MCF-7 cells and expression of ERalpha and PR. Food Chem Toxicol; 2001; 39(12):1225-32 Quartier S; Garmyn M; Becart S; Goossens A. Allergic contact dermatitis to copolymers in cosmetics--case report and review of the literature; Contact Dermatitis; 2006; 55(5):257-67 Smith SJ, Fenwick PS, Nicholson AG, Kirschenbaum F, Finney-Haywood Tk, Higgins LS, Giembycz MA, Barnes PJ, Donnelly LE: Inhibitors effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol, 149: 393-404; 2006. Sosman JA, Puzanov I: Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res, 12: 2376s-2383s; 2006. Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M: Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets, 6: 835-846; 2005. Sverdrup B; Klareskog L; Kleinau S. Common commercial cosmetic products induce arthritis in the DA rat.Environ Health Perspect;1998; 106(1):27-32 Thompson N, Lyon J: Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin